- Home
- PXED vs XNCR Comparison
PXED vs XNCR Comparison
Compare PXED & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PXED | XNCR |
|---|---|---|
| Founded | 1976 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PXED | XNCR |
|---|---|---|
| Price | $32.49 | $16.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $45.00 | $22.44 |
| AVG Volume (30 Days) | 107.6K | ★ 738.7K |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $1,007,192,000.00 | $150,132,000.00 |
| Revenue This Year | $4.15 | $18.81 |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | 6.02 | ★ 38.16 |
| 52 Week Low | $23.52 | $6.92 |
| 52 Week High | $47.08 | $26.59 |
Technical Indicators
Market Signals| Indicator | PXED | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.79 |
| Support Level | N/A | $16.44 |
| Resistance Level | N/A | $17.62 |
| Average True Range (ATR) | 0.00 | 0.93 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 0.00 | 36.50 |
Price Performance
Historical ComparisonAbout PXED Phoenix Education Partners Inc.
Phoenix Education Partners Inc is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. It is one of the online education providers and a pioneer in its field, the company benefits from the dynamic interplay between technological innovation, education, employment and economic trends. It is focused on delivering a personalized, career-relevant and affordable education to its students through its flexible learning model, skills-aligned curriculum and accessible tuition costs.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.